Here are a few analogies for Cardiol Therapeutics:

• Think of it as an early-stage Gilead Sciences or Amgen, but exclusively dedicated to developing novel therapies for cardiovascular diseases.

• It's like a nascent Moderna, but instead of mRNA vaccines, it's pioneering innovative drug delivery and compounds for treating heart conditions.

• Consider it a specialized Vertex Pharmaceuticals, but with its entire R&D pipeline focused on breakthrough treatments for various cardiovascular diseases.

• CardiolRx: A lead therapeutic product undergoing Phase II/III and Phase II (LANCER design) clinical trials for cardioprotection and reducing major cardiovascular and respiratory events, particularly in patients hospitalized with COVID-19.
• Proprietary subcutaneous formulation of cannabidiol: A treatment under development designed to achieve higher bioavailability for chronic heart failure.
• Proprietary nanotechnology: A platform technology being developed to enhance the distribution, pharmacokinetics, and accumulation of water-insoluble drugs in the failing heart.

Based on the provided company description, Cardiol Therapeutics Inc. is a clinical-stage life sciences company primarily focused on the research and development of therapeutic candidates for cardiovascular disease. Its lead products, such as CardiolRx, are currently in Phase II/III and Phase II clinical trials.

As a company in the clinical development stage, Cardiol Therapeutics Inc. does not yet have commercially approved products available for sale on the market. Therefore, it does not have major customers in the traditional sense of selling goods or services to other companies or individual consumers at this time.

David Elsley, President and Chief Executive Officer

Mr. Elsley is a business leader with a proven track record in developing, financing, and managing biotechnology and high-growth organizations. In 1990, he founded Vasogen Inc., a biotechnology company focused on therapeutics for heart failure and inflammatory conditions. Vasogen went public on both the TSX and Nasdaq, raising over $200 million and achieving a market capitalization exceeding US$1 billion. He managed Vasogen's growth from a start-up to an organization with over 250 employees and operations in Canada, the United States, and Europe, overseeing the advancement of two anti-inflammatory therapies through international multi-center pivotal Phase III clinical trials. Mr. Elsley also co-founded Cardiol Therapeutics in late 2016.

Chris Waddick, Chief Financial Officer and Corporate Secretary

Mr. Waddick has over thirty years of experience in financial and executive roles within the biotechnology and energy industries. He has served as CFO and Corporate Secretary of Cardiol since August 16, 2018. Prior to joining Cardiol, Mr. Waddick spent over twelve years at Vasogen Inc., a biotechnology company co-founded by David Elsley. There, as Chief Financial Officer and Chief Operating Officer, he helped grow the company from a start-up to an organization with over 250 employees. Vasogen went public on the TSX and NASDAQ, raising over $200 million and reaching a market capitalization of over US$1 billion. More recently, he served as Executive Vice President and Chief Financial Officer for a private Ontario energy company, where he was tasked with refinancing the company and establishing a new strategic direction.

Bernard Lim, Chief Operating Officer

Mr. Lim holds the position of Chief Operating Officer. In December 2024, he acquired 10,000 shares of Cardiol Therapeutics, bringing his total common share position to 40,000.

Anne Tomalin, Director of Regulatory Affairs

Ms. Tomalin has a strong background in business, government, regulations, and reimbursement policies, having practiced exclusively in regulatory affairs since 1971. In September 2013, she founded TPIreg Inc., a Regulatory Affairs and Quality Assurance company providing consulting services for Canada and the United States to the healthcare industry, which was acquired by Innomar Strategies in 2019. Prior to TPIreg, in September 1996, Ms. Tomalin founded CanReg Inc., which grew to become Canada's largest Regulatory Affairs consulting firm with over 100 staff.

Dolly Kao, Intellectual Property Counsel

Ms. Kao was appointed as Intellectual Patent Counsel for Cardiol Therapeutics in August 2018.

1. Clinical Trial and Regulatory Approval Risk: As a clinical-stage company, Cardiol Therapeutics' success is critically dependent on the outcomes of its ongoing clinical trials and subsequent regulatory approvals. The company's lead product, CardiolRx, is currently in a pivotal Phase III MAVERIC trial for recurrent pericarditis and has completed the Phase II ARCHER trial in acute myocarditis. There is a significant risk that these clinical trials may fail to demonstrate acceptable levels of safety and efficacy, or that regulatory authorities may require additional studies, which would extend timelines and increase costs. Any development or regulatory setback to CardiolRx could significantly impact the company's prospects and investment thesis.
2. Financial Sustainability and Capital Raising Risk: Cardiol Therapeutics currently lacks an approved commercial product, meaning it has no consistent source of regular income. The company incurs significant cash burn due to ongoing clinical studies and operational expenses. To fund its operations, Cardiol is frequently compelled to raise capital through issuing new stock or debt, which can lead to stock price impact and dilution of existing shareholders. For instance, Cardiol's cash runway of $30.6 million as of year-end 2024 was projected to fund operations only into the third quarter of 2026.
3. Product Pipeline and Competition Risk: Cardiol Therapeutics has a relatively shallow pipeline, with CardiolRx being its lead drug candidate. This singular focus amplifies the risk, as the company's future is largely tied to the success of this one product. Furthermore, the company operates in a highly competitive and evolving industry. For conditions like recurrent pericarditis, there is already an FDA-approved therapy on the market, which, despite being a third-line intervention, represents competition.

Cardiol Therapeutics Inc. (CRDL), a clinical-stage life sciences company, is poised for potential future revenue growth over the next 2-3 years primarily through the successful advancement and commercialization of its pipeline assets. Given the company's current lack of significant revenue and analyst forecasts predicting profitability within the next three years, these drivers hinge on clinical trial success and subsequent market entry.

The key drivers for Cardiol Therapeutics' future revenue growth are:

1. Commercialization of CardiolRx for Recurrent Pericarditis: CardiolRx, the company's lead product, is currently undergoing a pivotal Phase III MAVERIC trial for recurrent pericarditis. Enrollment for this trial is anticipated to conclude by the end of Q2 2026, with top-line results expected in the second half of 2026. Positive Phase II results for CardiolRx in recurrent pericarditis have already demonstrated significant improvements in pain, inflammation, and a reduction in recurrence rates. This indication is considered a primary near-term focus with the potential to address a "billion-dollar" market for an oral, non-immunosuppressive treatment option, especially given its Orphan Drug Designation from the FDA. Successful completion of the Phase III trial and subsequent regulatory approval and market launch would be the most immediate and substantial revenue driver for Cardiol Therapeutics.
2. Advancement of CRD-38 for Chronic Heart Failure: Cardiol is developing CRD-38, a novel subcutaneous formulation of cannabidiol, for the treatment of chronic heart failure, particularly heart failure with preserved ejection fraction (HFpEF). Pre-clinical findings have shown CRD-38's potential to improve cardiac function and reduce hypertrophy, remodeling, inflammation, and cell death. The progression of CRD-38 into later-stage clinical trials (Phase I/II and beyond) with positive results would open up a significant market opportunity in heart failure, a leading cause of hospitalization with substantial healthcare costs.
3. Potential Market Expansion of CardiolRx into Acute Myocarditis: CardiolRx has also been evaluated in the Phase II ARCHER study for acute myocarditis. While the trial's co-primary endpoints were not statistically met, the company observed some improvement in extracellular volume (ECV) and a significant reduction in left ventricular mass. Cardiol Therapeutics intends to integrate these findings into its broader clinical development strategy and business development initiatives. Should the company decide to pursue further clinical development (e.g., Phase III) for CardiolRx in acute myocarditis, successful trials and regulatory approval would create another significant revenue stream in a distinct cardiovascular disease market.
4. Leveraging Proprietary Nanotechnology for Enhanced Drug Delivery: Cardiol Therapeutics is developing proprietary nanotechnology designed to improve the distribution, pharmacokinetics, and accumulation of water-insoluble drugs, including cannabidiol, directly to inflammatory and fibrotic sites within the failing heart. This platform technology has demonstrated over a 100-fold increase in nanoparticle uptake in heart failure hearts during early studies. While not a direct product, the successful application and potential licensing or integration of this nanotechnology into current or future drug candidates could significantly enhance their efficacy and market potential, indirectly driving revenue growth through superior product offerings or strategic partnerships.

Share Issuance

• Cardiol Therapeutics' shares outstanding increased from 0.04 billion in June 2021 to 0.085 billion in September 2025, indicating significant share issuances over this period.
• The number of shares outstanding for CRDL increased by 21.91% in one year.
• As of March 10, 2026, Cardiol Therapeutics had 111.68 million shares outstanding, contributing to its market capitalization.

Inbound Investments

• Cardiol Therapeutics has raised additional capital to support its operations, as indicated by its cash runway analysis.
• As of March 2026, 45 institutional owners and shareholders hold a total of 9,268,987 shares in Cardiol Therapeutics.
• MMCAP International Inc. SPC significantly increased its holdings in Cardiol Therapeutics, reporting 17,451,746 shares in a January 2026 filing, a 628.48% increase from its previous holding.

Capital Expenditures

• In the most recent quarter, capital expenditures totaled -$0.0030, reflecting a minimal outlay.
• Over the last 12 months, capital expenditures amounted to -$19,783.